# Physiologically-based pharmacokinetic modelling of intravenously administered nanoformulated substances

Jordi Minnema1\*, Sven Even F. Borgos2, Neill Liptrott3, Rob Vandebriel1, Christiaan Delmaar1

1National Institute for Public Health and the Environment, Bilthoven, The Netherlands;

2SINTEF, Trondheim, Norway

3Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative biology, University of Liverpool, Liverpool, UK

\* Corresponding author; jordi.minnema@rivm.nl

## **Acknowledgments**

The present work has been developed within the REFINE project: Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices, funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement no 761104.

# **Abstract**


The use of nanobiomaterials (NBMs) is becoming increasingly popular in the field of medicine. To improve the understanding on the biodistribution of NBMs, the present study aimed to implement and parametrize a physiologically-based pharmacokinetic (PBPK) model. This model was used to describe the biodistribution of two NBMs after intravenous administration in rats, namely poly(alkyl cyanoacrylate) (PACA) loaded with cabazitaxel (PACA-Cbz) and LipImageTM 815.

A Bayesian parameter estimation approach was applied to parametrize the PBPK model using the biodistribution data. Parametrization was performed for two distinct dose groups of PACA-Cbz Furthermore, parametrizations were performed three distinct dose groups of LipImageTM 815, resulting in a total of five different parametrizations.

The results of this study indicate that the PBPK model can be adequately parametrized using biodistribution data. The PBPK parameters estimated for PACA-Cbz, specifically the vascular permeability, the partition coefficient and the renal clearance rate, substantially differed from those of LipImageTM 815. This emphasizes the presence of kinetic differences between the different formulations and substances and the need of tailoring the parametrization of PBPK models to the NBMs of interest. The kinetic parameters estimated in this study may help to establish a foundation for a more comprehensive database on NBM-specific kinetic information, which is a first, necessary step towards predictive biodistribution modelling. This effort should be supported by the development of robust *in vitro* methods to quantify kinetic parameters.

**Keywords:** Physiologically-based pharmacokinetic modelling; nanobiomaterials (NBMs); biodistribution; Bayesian parameter estimation

**Graphical Abstract**



# **Introduction**

Nanotechnology is rapidly gaining popularity in the field of medicine [1]. In medical settings, nanotechnology typically refers to the application of nanobiomaterials (NBMs) for surgical and medical treatments of patients. NBMs offer the opportunity of altering the associated pharmacokinetic profile of a drug, by improving dissolution in biological matrices, and prolonging systemic circulation time[2]. Since NBMs can be designed with a variety of physical-chemical characteristics, they can also be used in a variety of applications [3]. One way of applying NBMs is to encapsulate a drug with a NBM. Such encapsulated formulations can delay the elimination of the drug from the body, change their solubility or lower their toxicity [4]. Additionally, NBMs are particularly useful for targeted drug delivery, since the modified physical-chemical properties make is possible to target specific tissues or organs [5]. In fact, the application of NBMs is not limited to drug delivery, as they have also been used for medical imaging and diagnosis [6].

For many applications, NBMs are designed to alter the biodistribution of a substance of interest. In order to investigate whether designed NBMs exhibit the desired distribution characteristics, *in vitro* tests [7, 8] may be useful. For example, an *in vitro* assay has been developed to investigate the relation between phagocytic uptake and blood clearance [9]. However, the measured *in vitro* kinetics do not always translate to *in vivo* distributions. Moreover, they are usually specific to certain NBMs, and cannot always be used to infer generalities on the biodistribution of other NBMs. Hence, quantitative in vitro-to-in-vivo extrapolation (QIVIVE) remains challenging. As a consequence, researchers often still rely on animal experiments in order to investigate the biodistribution of NBMs. For instance, the biodistributions of various NBMs involving chemotherapeutic drugs have been investigated in mice, such as plitidepsin [10], cisplatin [11] and irinotecan [12]. Furthermore, the biodistribution of nanoformulated radiolabels was studied in mice [13] and rats [14].

A particularly useful tool to quantitatively describe the biodistribution of NBMs is that of physiologically‑based pharmacokinetic (PBPK) modelling. PBPK models represent particular body tissues and organs with interconnected compartments that exchange material with rates determined by physiological transport processes. PBPK models may be used to infer delivered doses at a tissue level, extrapolate experimentally determined biodistribution to different exposure conditions or even to predict the distribution of NBMs based on limited a priori kinetic information. A crucial step in effectively using PBPK models is finding appropriate values for the parameters defining the PBPK model (i.e., its ‘parametrization’). In practice, the parametrization is determined from experimental *in vivo* biodistribution data using a model-fitting procedure. The specific numerical values of the parameters estimated with such a procedure may be subject to large uncertainties, due to variability and imprecision in the data and due to a lack of identifiability of parameters. Also, *in vivo* biodistribution studies are expensive in terms of resources as well as animal life. Potentially, parametrization of PBPK models could be greatly aided with adequate *in vitro* testing systems that are predictive of specific kinetic processes or even PBPK model parameters [15]. Firstly, *in vitro* measurements can serve as initial (*a priori*) information in the interpretation of *in vivo* data by setting ranges on possible parameter values. Such information will significantly improve the parameter estimation from limited data. Second, and more importantly, *in vitro* kinetic information for critical, NBM-dependent model parameters can aid in the extrapolation of a PBPK model from one (well parametrized) NBM to another (i.e. read-across). In this way, *in vitro* testing could assist in the effort to replace, reduce and refine (i.e., 3Rs principle) animal studies that are still widely used as a first step towards clinical trials involving NBMs.

To effectively implement a pipeline that includes *in vitro* determination of kinetic parameters, several aspects need to be established. First, relevant *in vitro* systems must be available to represent physiological aspects that can be adequately quantified and included in a PBPK model. Second, the modelling should be able to effectively incorporate *a priori* information obtained from the *in vitro* system. Third, with respect to the objective of read-across of PBPK modelling, cataloging of critical kinetic model parameters is required. This third step includes the identification of generic parameters that do not vary much between NBMs, parameters that are specific to an NBM and may vary strongly between NBMs, and parameters for which the PBPK model is not very sensitive, so that acquiring very precise information for these parameters is not useful. Such a catalog of PBPK parameter information requires an extensive set of studies on a wide variety of NBMs. To date,few studies have been published in which PBPK models have been parametrized to describe the biodistribution of NBMs. For example, Dogra et al.[16] implemented a PBPK model to describe the biodistribution of nanoparticles based on their diameter, whereas Fallon et al. [17] used a PBPK model to describe the concentration profiles of amitriptyline nanoparticles (antidepressant drug). Furthermore, Rajoli et al [18, 19] implemented a PBPK model to describe the biodistribution of antiretrovirals with physicochemical properties that are compatible with nanoformulations. PBPK models have been applied relatively often to describe the biodistribution of liposomal NBMs such as Doxil® [20, 21] and AmBisome® [20, 22]. However, this dataset is still too limited to serve as a basis for a robust parameter cataloging. Additional PBPK studies are needed.

The present study therefore implements a PBPK model and parametrizes the model based on *in vivo* biodistribution data for two different NBMs. The first NBM consists of poly(alkyl cyanoacrylate) (PACA) nanoparticles (NPs) loaded with the chemotherapeutical drug, cabazitaxel. The second NBM consists of nanostructured lipid carriers loaded with the fluorescent dye IR780. In order to estimate the PBPK model parameters, *in vivo* biodistribution data of the two substances in rat were used. The biodistribution of the loaded substances is hypothesized to follow that of the encapsulating NBM. Model parameters characterizing the distribution of these NBMs are estimated and analyzed with respect to the extent with which they may be properly estimated from the data and the sensitivity of the model to them. Model parameters are compared cross-NBM to build hypotheses on generic model parameters that may be representative of larger groups of NBMs. To the best of our knowledge, this is the first study to parametrize PBPK models to simulate the biodistribution of PACA loaded with cabazitaxel and LipImageTM 815.

# **Materials and Methods**

## **2.1 *In vivo* biodistribution datasets**

In order to parametrize a PBPK model to describe the biodistribution of nanoparticles, dedicated *in vivo* biodistribution data are needed. In this study, two different biodistribution datasets were used, which were both based on studies in rat. The first biodistribution dataset was obtained following intravenous (iv) administration of PACA NBMs loaded with cabazitaxel (PACA-Cbz) [23]. These PACA NBMs can be used as drug-loading carriers since they facilitate targeted delivery of the chemotherapeutic drug to the tumor site [24]. The dataset was obtained by measuring cabazitaxel concentrations in various organs after administration of the PACA-Cbz. The second dataset was obtained following iv administration of LipImageTM 815 [23]. LipImageTM 815 is a novel contrast agent used in near-infrared fluorescence imaging [25]. It consists of nanostructured lipid carriers that are loaded with the fluorescent dye IR780. The concentration of this fluorescent ICG dye was measured in rat organs. Details of both datasets are given below.

### *PACA-Cbz*

A biodistribution study has been performed which involved a single administration of PACA NBMs loaded with the drug cabazitaxel (PACA-Cbz) produced by SINTEF (Trondheim, Norway). Cabazitaxel is a chemotherapeutic agent that has been approved by the U.S. food and drug administration (FDA) for the treatment of patients with metastatic prostate cancer. The PACA nanocarriers consisted of poly(2-ethylbutyl cyanoacrylate) (PEBCA). The particle hydrodynamic diameter and zeta potential of the PACA-Cbz NBM were determined using dynamic light scattering (DLS), which resulted in 121.8 nm (z-avg) and -5.5 mV, respectively [23]. In addition, a polydispersity index (PDI) of 0.14 was measured [23].

In this biodistribution study, PACA-Cbz was administered iv with two distinct cabazitaxel doses of 0.5 μg/g body weight, and 3.5 μg/g body weight. Cabazitaxel concentrations in blood were measured using a puncture after 1min, 3min, 7min, 15min, 30min, 1h, 4h, 1d, 2d, 4d and 14d. The biodistribution of the encapsulating PACA NBMs was assumed to follow that of the Cabazitaxel. Rats were sacrificed at five different time points: 1h, 1d, 2d, 4d, and 14d post‑exposure. At each time point, four rats were sacrificed. After sacrifice, cabazitaxel concentrations in blood, liver, spleen, lungs, kidneys, heart and brain were established. These data were used to parametrize the PBPK models in the present study. Further details on the PACA-Cbz biodistribution will be published by Åslund et al. [23].

### *LipImageTM 815*

The biodistribution of LipImageTM 815 has been assessed in a dedicated experiment, which was based on a single iv administration. LipImageTM 815 is produced by the French Alternative Energies and Atomic Energy Commission (CEA) and consists of a nanostructured lipid carrier that is loaded with IR780 [25]. The particle hydrodynamic diameter of LipImageTM 815 was determined using dynamic light scattering (DLS), which resulted in 52.2 nm (z-avg) [23]. In addition, a polydispersity index (PDI) of 0.102 was measured [23]. The zeta potential of LipImageTM 815 is neutral (0 mV) [23].

In the dedicated biodistribution study, three different dose group were used, which corresponded with IR780 doses of 0.046 μg/g body weight, 0.15 μg/g body weight and 0.46 μg/g body weight. Similar to the PACA-Cbz dataset, IR780 levels were measured in blood using a puncture 15min, 30min, 1h, 4h and 24h post-exposure. The biodistribution of the lipid NBMs was assumed to follow that of the IR780. Rats were sacrificed at 1h, 1d, 2d, 4d and 14d post‑exposure. After the sacrifice, blood, liver, spleen, lungs, kidneys, heart and brain were collected for IR780 analysis. Although IR780 levels were also measured in the thymus and the testes, these data were not considered in this study since those organs are not explicitly included in our PBPK model. Further details on this LipImageTM 815 biodistribution dataset will be published by Åslund et al. [23].


Table 1 summarizes the doses and measurement time points of the five biodistribution subsets.

**Table 1** Summary of the biodistribution datasets used to parametrize the PBPK models in the present study

|  |  |  |
| --- | --- | --- |
| **Dataset** | **Loaded substance concentration (μg/g bw)** | **Time points of sacrifice (h)** |
| PACA-Cbz | 0.5 | 1h, 1d, 2d, 4d and 14d |
| PACA-Cbz | 3.5 | 1h, 1d, 2d, 4d and 14d |
| *LipImageTM 815* | 0.046 | 1h, 1d, 2d, 4d and 14d |
| *LipImageTM 815* | 0.15 | 1h, 1d, 2d, 4d and 14d |
| *LipImageTM 815* | 0.46 | 1h, 1d, 2d, 4d and 14d |

## **2.2 PBPK model framework**

The PBPK model implemented in this study was originally developed by Li et al. [26] to describe distribution of nano CeO2 in rat. Fourteen main compartments are included in this model, namely, arterial blood, venous blood, upper airways, tracheobronchial region, pulmonary region, liver, spleen, kidney, heart, brain, gastro-intestinal (GI) tract, and the remaining organs (rest). All compartments are interconnected via the blood circulation. In addition, eight organ compartments comprised a sub-compartment that corresponds with the phagocytizing cells. Finally, four different clearance routes are included in this PBPK model: the lymphatic system, the urine, the feces, and liver metabolism. A schematic overview of the PBPK model is shown in Figure 1. Since the PBPK model was applied to simulate biodistributions after iv administration, the total injected dose was modelled to be deposited in the arterial blood compartment.



**Fig 1** Schematic overview of the PBPK model used in the present study. This PBPK model was adapted from Li et al. [26]

## **2.3 PBPK model parameter estimation**

To estimate the PBPK model parameters, a Bayesian method was adopted. Bayesian parameter estimation has the advantage that prior information on possible parameter values can be taken into account from previous experiments or literature. Furthermore, new information from various sources (e.g., expert judgement, in-vitro test results, kinetic parameters) can be incorporated via the prior when this information becomes available. This essentially allows one to refine and update model parameter information when new experimental datasets are acquired. Bayesian parameter estimation approaches are based on Bayes’ theorem, which is formulated as follows:

1).

represents the set of model parameters and *D* represents an observed data (e.g., measured concentrations or amounts in different organs). On the left-hand side of the equation is the posterior likelihood distribution, , the likelihood of parameter values given the data *D*. This can be interpreted as a probability distribution of the values for the parameter , i.e. as the parameter estimate. is the prior distribution, which expresses knowledge on the parameter values before evidence *D* is considered (e.g., evidence available from previous studies, based on read-across from similar materials or obtained from a representative *in vitro* test system). is the data likelihood. This expresses how well the PBPK model describes the observed data *D* for a particular set of parameters . represents the total likelihood of the data *D*. It is used as a normalization factor for the posterior.

Generally, solving eq 1) is complicated in view of the integration in the normalization factor (the total data likelihood). The technique of Markov (or Gibbs) sampling allows one to sidestep the complexities of the integration and to sample directly from the posterior likelihood distribution . This method follows from the observation that the normalization factor in 1) is a constant. The posterior is thus proportional to the product of the prior and the likelihood:

2).

Sampling from is therefore equivalent to sampling from the normalized posterior in 1).

The data likelihood is customarily assumed to depend on the difference between data simulated by a model with parameters and observed data. In this study, it was defined as follows.

3).

Here, *N* is the total number of observed data points, is the *i*th observed data point and is the corresponding predicted data point.

An adaptive Markov Chain Monte Carlo (MCMC) sampling method was employed to sample from the posterior likelihood, which was previously described by Vihola et al. [27]. Since prior information on model parameters was not available, the so-called uninformed prior (Jeffreys’ prior) was used [28], which initially places minimal constraints on the values the model parameters may take on. However, when considering the entire parameter space, sampling sufficient points to describe the posterior distribution proved to be prohibitively expensive, computationally. Therefore, upper and lower limits were set for each parameter. To identify reasonable limits, model parameters were manually optimized until the resulting model simulations visually resembled the observed biodistribution data to a reasonable degree. The upper and lower limits were then defined as a factor 30 higher and lower, respectively, than the manually optimized parameter values.

In addition to the upper and lower parameter limits, we also chose to only optimize a limited number of model parameters. These parameter values were chosen by inspecting their influence on the PBPK model outcomes based on the model equations. The following parameters, as well as the corresponding upper and lower limits used in the MCMC sampling method are shown in Table 2.

**Table 2** Model parameter chosen to be optimized, as well as their upper and lower limits used in the MCMC method

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter [unit]** | **Upper/lower limits**  **(PACA-Cbz** | **Upper/lower limits (LipImageTM 815*)*** | **Description** |
| χrich [-] | 1.67×10-2 – 15 | 1.67×10-1 – 150 | Permeability of richly perfused organs |
| P [-] | 3.3×10-2 – 30 | 1.67×10-3 – 1.5 | Tissue-blood partition coefficient |
| kkidneyEl [h-1] | 1 – 900 | 3.3×10-2 – 30 | Renal elimination rate |
| kab0 [h-1] | 1.16×10-2 – 10.5 | 3.3×10-2 – 30 | The maximum uptake rate of phagocytizing cells in organs except for the spleen |
| ksab0 [h-1] | 1.67×10-2 – 15 | 3.3×10-2 – 30 | The maximum uptake rate of phagocytizing cells in the spleen |
| kde [h-1] | 3.3×10-5 – 0.03 | 3.3×10-5 – 0.03 | The release rate of phagocytizing cells |

The remaining model parameters were adopted from Li et al. [26] Although their study results are based on different NPs and exposure scenarios, the influence of the remaining model parameters on the model outcome is small. This assumption was verified using a local sensitivity analysis (results not shown). This local sensitivity analysis was performed by calculating the area under the curve (AUC) of the NBM amounts in the blood compartments (venous + arterial). In addition, the sensitivity analysis was performed for one parameter at a time, hence the sensitivity of combined parameters was not assessed. Specifically, the sensitivity was calculated in the form of an elasticity coefficient S:

Where is the change in the as a result of a change in the parameter value, . Here, the applied change in the parameter values was always 10% of the original value,, which means that .

The PBPK model, the adaptive MCMC parameter sampling method and the sensitivity analyses were implemented in R [29] using the packages mrgSolve [30] and adaptMCMC [31].

## **Model evaluation**

A PBPK model was independently parametrized using the Bayesian parameter estimation approach for each of the five biodistribution data groups, (i.e., the two dose groups of PACA-Cbz, and the three dose groups of LipImageTM 815). In order to quantitatively evaluate the quality of the PBPK model simulations, the average absolute fold error (AAFE) was calculated, which is defined as follows:


4).

where *N* denotes the total number of observations. Note that the AAFE was calculated separately for each parametrized model, and for each model compartment. An AAFE of 1 is achieved when the PBPK model simulation exactly matches the measured biodistribution data. The AAFE increases as the difference between the PBPK model prediction and the measured data increases.

# **Results**

In the present study, a PBPK model was parametrized based on five *in vivo* biodistribution (sub)datasets concerning NBMs. Figure 2 shows the posterior distribution of each parameter estimated using the five biodistribution datasets. These posterior distributions are probability density plots of the parameter values after considering the biodistribution data. This means that gives the probability that a parameter has a value between and . As shown in Figure 2, the posterior distribution of χrich is rather broad, covering at least two or more orders of magnitude in all five parametrizations. In addition, no clear maximum is observed in the posterior distributions of χrich for the LipImageTM 815 datasets. The posterior distributions of the remaining parameters were generally narrower (i.e., smaller than one order of magnitude) and always demonstrated a clear maximum.

In order to investigate whether PBPK parameters were correlated, pair-plots were made (supplemental material; Figures S1-S5). Generally, no correlations were observed between the PBPK parameters. Only the macrophage uptake parameters, kab0 and ksab0, seemed to exhibit a linear relationship when considering the parameter estimates based on the PACA-Cbz low dose biodistribution data (Figure S1).



**Fig 2** Probability density plots of the sampled posterior distributions of the six estimated parameters (i.e.,χrich, P, kab0, ksab0, kkidneyEl and kde) for the five in vivo biodistribution datasets


Table 3 shows the median value and the credible interval of the posterior distributions of all parameters and all five *in vivo* data subsets. The median value represents the most likely parameter value and will be referred to as the parameter estimate. The credible interval is the interval that contains 90% of the parameter values in the posterior distribution.

The results presented in Table 3 demonstrate that the estimated permeability of richly perfused organs, χrich, and the estimated renal clearance, kkidneyEl were approximately two orders of magnitude larger for PACA-Cbz than for LipImageTM 815. Similarly, the substance-blood partition coefficient, *P,* is approximately one order of magnitude larger for PACA-Cbz than for LipImageTM 815. The macrophage absorption rate parameters, kab0,ksab0 and the macrophage release rate, kde, were comparable between PACA-Cbz and LipImageTM 815. Interestingly, *P*, ksab0, and kkidneElall increase with increasing LipImageTM 815 doses. Such a dose-dependent relation was only observed for the ksab0 when assessing PACA-Cbz.

**Table 3** Parameter estimates (median) and the corresponding credible interval (in parentheses) resulting from applying the Bayesian parameter estimation method using the five biodistribution datasets. χrich: Vascular permeability coefficient; P: partition coefficient; kkidneyEl: renal clearance rate; kab0: uptake rate by macrophages (excluding those in the spleen); ksab0: uptake rate by macrophages in the spleen; kde: release rate by macrophages


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Dataset** | **χrich** | **P** | **kkidneyEl** | **kab0** | **ksabo** | **kde** |
| *PACA-Cbz Low* | **1.5**  (1.6**×**10-1 – 1.3**×**101) | **3.9**  (2.4 – 5.4) | **2.4×102**  (1.9**×**102 – 3.2**×**102) | **1.3×10-2**  (1.2**×**10-2 – 4.4**×**10-2) | **8.4×10-2**  (5.4**×**10-2 – 2.6**×**10-1) | **1.4×10-2**  (1.2**×**10-2 – 2.5**×**10-2) |
| *PACA-Cbz High* | **2.1**  (1.7**×**10-2 – 1.3**×**102) | **2.6**  (1.7 – 4.0) | **2.1×102**  (1.7**×**102 – 2.8**×**102) | **1.4×10-2**  (1.2**×**10-2 – 2.5**×**10-2) | **2.3×10-1**  (1.4**×**10-1 – 4.3**×**10-1) | **1.4×10-2**  (1.3**×**10-2 – 1.9**×**10-2) |
| *LipImageTM 815 Low* | **7.0**  (2.4**×**10‑1 - 1.2**×**102) | **1.3**×**10-1**  (5.0**×**10-2 – 2.2**×**10-1) | **2.7**  (2.1 – 3.4) | **1.7**×**10-1**  (8.3**×**10-2 – 8.0**×**10-1) | **2.1**×**10-1**  (1.0**×**10-1 – 8.7**×**10-1) | **1.3×10-2**  (7.6**×**10-3 – 2.6**×**10-2) |
| *LipImageTM 815 Mid* | **5.4**  (2.4**×**10‑1 – 11) | **1.7**×**10-1**  (8.4**×**10-2 – 2.8**×**10-1) | **4.3**  (3.3 – 5.4) | **1.6×10-1**  (9.3**×**10-2 – 4.6**×**10-1) | **3.0×10-1**  (1.7**×**10-1 – 8.4**×**10-1) | **8.6×10-3**  (5.5**×**10-3-1.5**×**10-2) |
| *LipImageTM 815 High* | **4.5**  (2.3**×**10‑1 – 98) | **2.8×10-1**  (1.6**×**10-1 – 4.6**×**10-1) | **7.9**  (6.2 – 10) | **2.6×10-1**  (1.1**×**10-1 – 6.4**×**10-1) | **4.7×10-1**  (2.2**×**10-1 – 1.1) | **1.3×10-2**  (7.0**×**10-3 – 2.2**×**10-2) |

The median parameter estimates shown in Table 3 were used to simulate cabazitaxel and IR780 levels. Figure 3 shows a comparison between the simulated cabazitaxel levels and those measured *in vivo*. The difference between the simulated cabazitaxel levels and the measured cabazitaxel levels was expressed with the AAFE, which is also shown in Figure 3.



**Fig 3** PBPK model simulation results (red) compared with measured cabazitaxel (black dots) in blood plasma, liver, spleen, lung, brain, heart and kidney for two different doses. The difference between simulated and measured cabazitaxel levels, which is expressed with the AAFE, is shown in the right-upper corner of every plot. A larger AAFE corresponds with a larger difference, and an AAFE of 1 represents a perfect fit

For each of the three LipImageTM 815 dose groups, simulated and corresponding measured IR780 levels are shown in Figure 4. IR780 simulations are shown for the blood, liver, spleen, lung, brain, heart and kidney. The difference between the simulated IR780 levels and the measured IR780 levels was expressed with the AAFE, which is also shown in Figure 4. All AAFEs calculated for IR780 were below 3, indicating an average discrepancy between model and data of less than a factor 3. In addition, the AAFEs resulting from the spleen and the heart were always below 2, whereas the AAFE corresponding to blood, lungs and brain were higher than 2 for all three dose groups.



**Fig 4** PBPK model simulation results (red) compared with measured IR780 (black) in blood plasma, liver, spleen, lung, brain, heart and kidney for three different LipImageTM 815 doses. The difference between simulated and measured IR780 levels, which is expressed with the AAFE, is shown in the right-upper corner of every plot. A larger AAFE corresponds with a larger difference, and an AAFE of 1 represents a perfect fit

## **Discussion**

The use of NBMs has become a very promising approach to facilitate various medical applications including targeted drug delivery and medical imaging [32]. One of the key aspects for adequately using the NBMs, is the optimization of the biodistribution of a substance by selecting the encapsulating NP [33]. The present study utilized a PBPK model to analyze the *in vivo* biodistribution of two NBMs after iv administration in rats. The NBMs considered in this work were PACA loaded with cabazitaxel particles and LipImageTM 815. Using a Bayesian parameter estimation technique, PBPK model parameters were estimated from *in vivo* biodistribution data. The Bayesian method is particularly suitable as it naturally accommodates the introduction of *a priori* information via a so-called ‘prior’. In principle, this method also allows the incorporation of initial model parameters measured in *in vitro* models. Ideally, an appropriate *in vitro* system may provide at least a correct order-of-magnitude estimate of a parameter’s value. This estimate may then be used to define a prior distribution, which can then be updated with e.g. *in vivo* data. Limiting a search to a smaller region of the parameter space via an informed prior will significantly improve parameter estimation from distribution data.

The PBPK model parametrizations obtained in this study resulted in accurate simulations of PACA-Cbz and LipImageTM 815 concentrations. This indicates that the parameter estimation was successful. Interestingly, the parameter estimates resulting from the parametrization on the biodistribution data of PACA-Cbz were markedly different from parameter estimates resulting from the parametrization on the LipImageTM 815 biodistribution data (Table 3). More specifically, the estimated permeability of richly perfused organs, χrich, and the estimated renal clearance, kkidneyEl were approximately two orders of magnitude larger for PACA-Cbz than for LipImageTM 815, whereas the partition coefficient, P, was approximately one order of magnitude smaller for PACA-Cbz than for LipImageTM 815. Furthermore, the estimates of these three parameters based on PACA-Cbz, fall outside the credible interval of the parameter estimated for LipImageTM 815. These findings may be (partially) explained by the different physicochemical properties of the two studied NBMs. Specifically, the zeta potential and the particle size substantially differed, which might have affected the biodistribution of the NBMs. This further emphasizes the need of tailoring the parametrization of PBPK models to the substance of interest. Conversely, the macrophage related parameters kab0,ksab0 (macrophage absorption rate) and kde (macrophage release rate) seemed comparable among the considered NBMs. Whilst already known that macrophage uptake of nanoparticles is a key component of the biodistribution and biocompatibility of NBMs [34], the work presented here highlights the importance of clear determination of macrophage accumulation of NBMs, irrespective of the nanoparticle platform. Ongoing work within the REFINE consortium, is aimed at defining, and translating methodologies to assess macrophage uptake of NBMs, that can aid in PBPK model development.

Information on PBPK model parameters as collected here will significantly aid the generalizability of PBPK modelling. If the database on specific model parameters is expanded, this could allow the grouping of NBMs according to kinetic parameters. Regression modelling or classification models could assist in predicting model parameters based on NBM properties, or at least assist in constructing prior distributions, thus greatly improving subsequent model parametrizations. Ideally, such a database could be supported by adequate *in vitro* measurements of kinetic parameters, further strengthening the development of informed, predictive priors for the parameter. An example of a PBPK model parameter that could be directly measured in *in vitro* systems is the permeability of the vascular epithelium (‘χrich’) [35]. In addition, NBM uptake by phagocytes (‘kab0’, ‘ksab0’) may be measured by incubating macrophages with fluorescently labelled NBMs and subsequently detecting fluorescence using a plate reader, flow cytometry or confocal microscopy [36]. Future studies should be conducted to compare *in vitro* measurements of PBPK model parameters for the NBMs considered in this work, in order to evaluate the feasibility of the *in vitro* system for PBPK model parametrization.

Another important finding of this study was that certain parameters estimated using the LipImageTM 815 biodistribution data seemed to be dose-dependent. In particular, the partition coefficient P, the uptake rate of macrophages in the spleen, ksab0, and the renal clearance kkidneyEl all increased with increasing dose (Table 3). In addition, minor to no overlap was found between the credible intervals of these parameter estimates between the different parametrizations. In contrast, the permeability χrich, the uptake rate of macrophages outside the spleen kab0, and the release rate from macrophages kde, did not demonstrate clear trends with increasing dose. This indicates that certain PBPK model parameters should be tailored to the desired LipImageTM 815 dose of the exposure scenario. The dose-dependency of certain model parameters might limit the extrapolation of LipImageTM 815 biodistribution data to different doses. Interestingly, for the PACA-Cbz biodistribution this dose-dependency was only observed for the kab0. Further research should be conducted to investigate whether the dose-dependency of PBPK model parameters is seen for other NBMs, and to identify other PBPK model parameters that might exhibit a dose dependency.

In the present study, a PBPK model was used to simulate the biodistribution of two NBMs. The biodistribution of the encapsulating NBMs is assumed to follow that of the substances loaded, since the biodistribution is mainly governed by the characteristics of the encapsulating NBM. However, this approach does not take into account the distribution of the free substances. As the encapsulating NBM degrades at a certain rate after administration, the loaded substance is released after which it may still migrate through the body, albeit with different kinetics than that of the NBM. In order to also consider the biodistribution of the free substance, a complementary model for the distribution and elimination of the free substance should be implemented and parametrized. Parametrization of this model would require measuring the encapsulated substance as well as the free substance. However, due to the technical challenges in making this distinction, there are currently no biodistribution datasets available that include this information. As a consequence, it remains challenging to incorporate the kinetics of the free substance into the PBPK model.

The present study shows that PBPK models can be well parametrized from biodistribution data for two NBMs, namely PACA-Cbz and LipImageTM 815. In order to advance the applicability of PBPK modelling of the NBMs, data on specific PBPK model parameters should be expanded and preferably be compiled in a generally accessible database. Such a database would support the identification of groups of PBPK model parameters that are fairly constant across (a group of) NBMs, and of parameters that appear to be NBM-specific and require quantification on a case by case basis. Especially for the latter, the availability of adequate *in vitro* systems to estimate their values would greatly expand the generalizability of PBPK models. It should be noted, however, that a challenge in setting up such a database is that many different PBPK models have been developed, making the comparison between parameter estimates difficult. The database should therefore also include the model structure used to derive the parameter values. This model structure should be considered when searching for relations between estimated parameters and NBM properties.

Ideally, a PBPK model would be developed that predicts the biodistribution in humans, instead of animals such as rats. Although such human PBPK models have been developed for a few substances [37-41], validation of their predictivity is extremely challenging due to a lack of human biodistribution data involving NBMs. Instead of tackling this challenge at once, we aimed to first work towards a predictive model for rats. Such a model allows us to obtain a better understanding of the NBM properties in relation to the kinetic PBPK model parameters. The two most important steps to arrive at that stage are 1) the collection of more *in vivo* biodistribution data to expand the database and enable the identification of trends in kinetic properties and grouping of NBMs and 2) the development of robust and reliable in vitro methods that provide quantitative parameters that can be directly incorporated in a PBPK model. Although the second step is one of the objectives within the REFINE consortium, neither condition has yet been fulfilled. The present work contributes to the expansion of the database on kinetic parameters.

## **Conclusion**

This work presents the parametrization of a PBPK model on the basis of biodistribution data for two NBMs, PACA-Cbz and LipImageTM 815. Some of the identified PBPK model parameter values (i.e., the macrophage uptake and release parameters) were fairly constant over the different NBMs and dosing schedules. In contrast, parameters related to elimination, partitioning and vascular permeability were clearly material-dependent. Overall, the parametrized PBPK model provided a good description of the distribution data, indicating the validity of the approach. However, the study also demonstrated dose-dependency in certain parameters when parametrizing the PBPK model using the LipImageTM 815 biodistribution data, which implies that the administered dose must be carefully considered when interpreting PBPK model simulations.

All in all, this study helps with expanding the dataset on PBPK model parameters for different NBMs. It should be noted that the parametrization was performed with the implicit assumption that the distribution is mainly driven by the distribution of the encapsulating NBM and that after degradation of the NBM, subsequent re-distribution of the loaded substance does not occur to a significant extent. This introduces some uncertainty in the quantitative results. It is important to stress that future PBPK studies should ideally keep track of both NBM and encapsulated drug. This would enable the development of generic, predictive PBPK models. This effort should be supported by the development of robust *in vitro* methods to quantify kinetic parameters. Some *in vitro* systems have already been developed for NBMs, but it is vital to understand variability in methodological approaches, to harmonize assessment of these key parameters. The results of this study furthermore show that the Bayesian parameter estimation method is a useful tool to parametrize a PBPK model. The Bayesian method is especially apt to combine information from different sources, be it different *in vivo* studies or *in vitro* data. Together with generic PBPK modelling, the Bayesian parametrization approach and *in vitro* kinetic models could greatly assist in the effort to replace, reduce and refine (i.e., 3Rs principle) animal studies.

## **Ethical Statement:**

* Ethics approval and consent to participate: Not applicable
* Consent for publication: Not applicable
* Availability of data and materials: Not applicable
* Competing interests: The authors have no relevant financial or non-financial interests to disclose.
* Funding: The present work has been developed within the REFINE project: Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices, funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement no. 761104.
* Authors' contributions: All authors contributed to the study design. Material collection, data analysis and code development were performed by Jordi Minnema and Christiaan Delmaar. The first draft of the manuscript was written by Jordi Minnema and all authors commented on previous version of the manuscript. All authors have read and approved the final manuscript.
* Acknowledgements: Not applicable

## **References**

1. De Jong, W.H. and P.J. Borm, *Drug delivery and nanoparticles:applications and hazards.* Int J Nanomedicine, 2008. **3**(2): p. 133-49.

2. Khan, I., K. Saeed, and I. Khan, *Nanoparticles: Properties, applications and toxicities.* Arabian Journal of Chemistry, 2019. **12**(7): p. 908-931.

3. Salata, O., *Applications of nanoparticles in biology and medicine.* J Nanobiotechnology, 2004. **2**(1): p. 3.

4. Sanchez, A., S.P. Mejia, and J. Orozco, *Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections.* Molecules, 2020. **25**(16).

5. Sindhwani, S. and W.C.W. Chan, *Nanotechnology for modern medicine: next step towards clinical translation.* J Intern Med, 2021.

6. Abdussalam-Mohammed, W., *Review of Therapeutic Applications of Nanotechnology in Medicine Field and its Side Effects.* Journal of Chemical Reviews, 2019. **1**(3): p. 243-251.

7. Bahmani, B., et al., *Effects of nanoencapsulation and PEGylation on biodistribution of indocyanine green in healthy mice: quantitative fluorescence imaging and analysis of organs.* Int J Nanomedicine, 2013. **8**: p. 1609-20.

8. Witika, B.A., et al., *Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches.* Nanomaterials (Basel), 2020. **10**(9).

9. Zhang, Y., et al., *A Systematic comparison of in vitro cell uptake and in vivo biodistribution for three classes of gold nanoparticles with saturated PEG coatings.* PLoS One, 2020. **15**(7): p. e0234916.

10. Oliveira, H., et al., *Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.* Pharm Res, 2014. **31**(4): p. 983-91.

11. Li, J., et al., *In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.* Nanomedicine, 2014. **10**(7): p. 1465-75.

12. Atyabi, F., et al., *Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.* Acta Pharm, 2009. **59**(2): p. 133-44.

13. Tang, C., et al., *Biodistribution and fate of core-labeled (125)I polymeric nanocarriers prepared by Flash NanoPrecipitation (FNP).* J Mater Chem B, 2016. **4**(14): p. 2428-2434.

14. Tsotsalas, M.M., et al., *Encapsulating (111)In in nanocontainers for scintigraphic imaging: synthesis, characterization, and in vivo biodistribution.* ACS Nano, 2010. **4**(1): p. 342-8.

15. Utembe, W., et al., *Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials.* Nanomaterials (Basel), 2020. **10**(7).

16. Dogra, P., et al., *Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors.* Annu Int Conf IEEE Eng Med Biol Soc, 2019. **2019**: p. 2852-2855.

17. Fallon, M.S., et al., *A physiologically-based pharmacokinetic model of drug detoxification by nanoparticles.* J Pharmacokinet Pharmacodyn, 2004. **31**(5): p. 381-400.

18. Rajoli, R.K.R., et al., *Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.* Eur J Pharm Biopharm, 2019. **144**: p. 101-109.

19. Rajoli, R.K.R., et al., *In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.* Clin Pharmacokinet, 2018. **57**(2): p. 255-266.

20. Nagpal, S., et al., *A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.* Eur J Pharm Biopharm, 2020. **153**: p. 257-272.

21. He, H., et al., *A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.* Pharm Res, 2018. **35**(9): p. 174.

22. Kagan, L., et al., *Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.* Pharm Res, 2014. **31**(1): p. 35-45.

23. Åslund, A.K.O., Vandebriel, R., Caputo, F., Jong, W.H., Delmaar, C., Hyldbakk, A., Rustique, E., Schmid, R., Snipstad, S., Texier, I., Vernstad, K., Borgos, S.E.F., *A comparative biodistribution study of polymeric and lipid-based nanoparticles.* Drug Delivery and Translational Research, 2022. **In submission**.

24. Ak, G., et al., *Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture.* Colloids and Surfaces B: Biointerfaces, 2021. **206**: p. 111946.

25. Jacquart, A., et al., *LipImage 815: novel dye-loaded lipid nanoparticles for long-term and sensitive in vivo near-infrared fluorescence imaging.* J Biomed Opt, 2013. **18**(10): p. 101311.

26. Li, D., et al., *In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles in rats.* Part Fibre Toxicol, 2016. **13**(1): p. 45.

27. Vihola, M., *Robust adaptive Metropolis algorithm with coerced acceptance rate.* Statistics and Computing, 2011. **22**(5): p. 997-1008.

28. Jeffreys, H., *An invariant form for the prior probability in estimation problems.* Proc R Soc Lond A Math Phys Sci, 1946. **186**(1007): p. 453-61.

29. R Core Team, A., *A language and environment for statistical computing.* R Foundation for Statistical Computing, 2021.

30. Baron, K.T., *mrgsolve: Simulate from ODE-Based Models*. 2021.

31. Scheidegger, A., *adaptMCMC: Implementation of a Generic Adaptive Monte Carlo Markov Chain*. 2021.

32. Noorlander, C.W., et al., *Horizon scan of nanomedicinal products.* Nanomedicine (Lond), 2015. **10**(10): p. 1599-608.

33. Su, S. and P.M. Kang, *Systemic Review of Biodegradable Nanomaterials in Nanomedicine.* Nanomaterials (Basel), 2020. **10**(4).

34. Gustafson, H.H., et al., *Nanoparticle Uptake: The Phagocyte Problem.* Nano Today, 2015. **10**(4): p. 487-510.

35. Cascone, S., G. Lamberti, and G. Titomanlio, *Designing in-vitro systems to simulate the in-vivo permeability of drugs.* Translational Medicine, 2014. **10**(5): p. 18-21.

36. Meindl, C., et al., *Comparison of fluorescence-based methods to determine nanoparticle uptake by phagocytes and non-phagocytic cells in vitro.* Toxicology, 2017. **378**: p. 25-36.

37. Sharma, R.P., M. Schuhmacher, and V. Kumar, *Development of a human physiologically based pharmacokinetic (PBPK) model for phthalate (DEHP) and its metabolites: A bottom up modeling approach.* Toxicol Lett, 2018. **296**: p. 152-162.

38. Liao, C.M., et al., *Lung cancer risk in relation to traffic-related nano/ultrafine particle-bound PAHs exposure: a preliminary probabilistic assessment.* J Hazard Mater, 2011. **190**(1-3): p. 150-8.

39. Bachler, G., N. von Goetz, and K. Hungerbuhler, *A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles.* Int J Nanomedicine, 2013. **8**: p. 3365-82.

40. Pery, A.R., et al., *Development of a physiologically based kinetic model for 99m-technetium-labelled carbon nanoparticles inhaled by humans.* Inhal Toxicol, 2009. **21**(13): p. 1099-107.

41. Hendriks, B.S., et al., *Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.* CPT Pharmacometrics Syst Pharmacol, 2012. **1**: p. e15.